Association and expression analyses with single-nucleotide polymorphisms in TOMM40 in Alzheimer disease

Archives of Neurology

Volumn 68, Issue 8, 2011, Pages 1013-1019

  Cruchaga, Carlos ^a   Nowotny, Petra ^a   Kauwe, John S K ^b   Ridge, Perry G ^b,c   Mayo, Kevin ^a   Bertelsen, Sarah ^a   Hinrichs, Anthony ^a   Fagan, Anne M ^a   Holtzman, David M ^a   Morris, John C ^a   Goate, Alison M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRIGHAM YOUNG UNIVERSITY   (United States)

^c ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E;

ADULT; AGED; ALZHEIMER DISEASE; APOE GENE; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; FEMALE; GENE; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENE REPLICATION; GENETIC ANALYSIS; GENOTYPE; HAPLOTYPE; HEREDITY; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYLOGENY; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEIN E3; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HAPLOTYPES; HOMOZYGOTE; HUMANS; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; POLY T; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 80051564625     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.155     Document Type: Article

References (27)

1. Grupe A, Abraham R, Li Y, et al. Evidence for novel susceptibility genes for late-onset Alzheimer's disease from a genome-wide association study of putative functional variants. Hum Mol Genet. 2007;16(8):865-873. (Pubitemid 47064316)
2. Coon KD, Myers AJ, Craig DW, et al. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry. 2007;68(4):613-618. (Pubitemid 46663046)
3. Reiman EM, Webster JA, Myers AJ, et al. GAB2 alleles modify Alzheimer's risk in APOE ε4 carriers. Neuron. 2007;54(5):713-720. (Pubitemid 46843528)
4. Bertram L, Lange C, Mullin K, et al. Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am J Hum Genet. 2008;83(5):623-632.
5. Li H, Wetten S, Li L, et al. Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol. 2008;65(1):45-53.
6. Carrasquillo MM, Zou F, Pankratz VS, et al. Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease. Nat Genet. 2009;41(2):192-198.
7. Züchner S, Wendland JR, Ashley-Koch AE, et al. Multiple rare SAPAP3 missense variants in trichotillomania and OCD. Mol Psychiatry. 2009;14(1):6-9.
8. Beecham GW, Martin ER, Li YJ, et al. Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. Am J Hum Genet. 2009;84(1):35-43.
9. Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009;41(10):1088-1093.
10. Lambert JC, Heath S, Even G, et al European Alzheimer's Disease Initiative Investigators. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009;41(10):1094- 1099.
11. Yu CE, Seltman H, Peskind ER, et al. Comprehensive analysis of APOE and selected proximate markers for late-onset Alzheimer's disease: patterns of linkage disequilibrium and disease/marker association. Genomics. 2007;89(6):655-665. (Pubitemid 46719797)
12. Roses AD, Lutz MW, Amrine-Madsen H, et al. A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease. Pharmacogenomics J. 2010;10(5):375-384.
13. Hong MG, Alexeyenko A, Lambert JC, Amouyel P, Prince JA. Genome-wide pathway analysis implicates intracellular transmembrane protein transport in Alzheimer disease. J Hum Genet. 2010;55(10):707-709.
14. Berg L, McKeel DW Jr, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol. 1998;55(3):326-335. (Pubitemid 28146197)
15. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939-944. (Pubitemid 14076461)
16. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans. Ann Neurol. 2006;59(3):512-519. (Pubitemid 43358072)
17. 42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64(3):343-349.
18. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009;65(4):403-413.
19. Imle P. Fluorescence-based fragment size analysis. Methods Mol Biol. 2005;311:139-146.
20. Myers AJ, Gibbs JR, Webster JA, et al. A survey of genetic human cortical gene expression. Nat Genet. 2007;39(12):1494-1499. (Pubitemid 350191339)
21. Cruchaga C, Kauwe JS, Mayo K, et al Alzheimer's Disease Neuroimaging Initiative. SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. PLoS Genet. 2010;6(9):pii: e1001101.
22. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet. 2003;73(5):1162-1169. (Pubitemid 37414228)
23. Huentelman MJ, Corneveaux J, Myers A, et al. Genome-wide association study for Alzheimer's disease risk in a large cohort of clinically characterized and neuropathologically verified subjects. In: ICAD-2010. Honolulu, Hawaii: Alzheimer's Association; 2010:16.
24. Kauwe JS, Cruchaga C, Mayo K, et al. Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-β deposition. Proc Natl Acad Sci U S A. 2008;105(23):8050-8054. (Pubitemid 351904706)
25. Kauwe JS, Jacquart S, Chakraverty S, et al. Extreme cerebrospinal fluid amyloid β levels identify family with late-onset Alzheimer's disease presenilin 1mutation. Ann Neurol. 2007;61(5):446-453. (Pubitemid 46878772)
26. Kauwe JS, Cruchaga C, Bertelsen S, et al Alzheimer's Disease Neuroimaging Initiative. Validating predicted biological effects of Alzheimer's disease associated SNPs using CSF biomarker levels. J Alzheimers Dis. 2010;21(3):833-842.
27. Jun G, Naj AC, Beecham GW, et al Alzheimer's Disease Genetics Consortium. Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol. 2010;67(12):1473-1484.